The market potential for 2DG is significant. Three million people in the United States suffer from epilepsy, and half of the them – 1.5 million people – have inadequately controlled forms of the disease that are not successfully treated with commercially available drugs. All of these patients are potential candidates for 2DG treatment.
In addition, 2DG may be proven to be a useful acute treatment after traumatic brain injury (TBI) to lessen the incidence of TBI associated epileptic seizure. Traumatic brain injury is common problem which is estimated to afflict as many as 1.7 million people in the US each year. This incidence does not include cases of TBI reported from military or Veterans Affairs hospitals, or milder forms of TBI such as concussion in the setting of athletic injuries. Consequences of TBI include long-term cognitive deficits, post-traumatic epilepsy (PTE), and post-traumatic stress disorder (PTSD).